Discover Oncology SCIE

國(guó)際簡(jiǎn)稱：Discov Oncol 參考譯名：探索腫瘤學(xué)

主要研究方向：Medicine-Endocrinology, Diabetes and Metabolism 非預(yù)警期刊審稿周期： 5 Weeks

《探索腫瘤學(xué)》(Discover Oncology)是一本由Springer Nature出版的以Medicine-Endocrinology, Diabetes and Metabolism為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開(kāi)放期刊，近三年沒(méi)有被列入預(yù)警名單。

4區(qū) 中科院分區(qū)
Q2 JCR分區(qū)
229 年發(fā)文量
2.8 IF影響因子
開(kāi)放 是否OA
English 出版語(yǔ)言

Discover Oncology is an international journal dedicated to the field of oncology, aiming to provide a platform for researchers, clinicians, and students worldwide to exchange and share the latest scientific research achievements. This journal covers various aspects of oncology, including basic research, clinical research, drug development, diagnostic techniques, treatment strategies, and more. This journal is committed to publishing high-quality original research papers, review articles, case reports, technical reports, etc. to promote scientific progress and technological innovation in the field of oncology. At the same time, the magazine also focuses on education and training in oncology, regularly publishing relevant teaching articles and guidelines. As a professional, authoritative, and open oncology journal, it provides a high-quality academic exchange platform for researchers and clinical doctors worldwide.

[ 查看全部 ]

投稿咨詢加急咨詢

Discover Oncology期刊信息

ISSN：2730-6011
出版語(yǔ)言：English
是否OA：開(kāi)放
E-ISSN：2730-6011
出版地區(qū)：Switzerland
是否預(yù)警：否
出版商：Springer Nature
開(kāi)源占比：0.9951
Gold OA文章占比：99.54%
OA被引用占比：
出版國(guó)人文章占比：0
出版撤稿占比：
研究類文章占比：83.84%

Discover Oncology CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

2.4

0.715

0.527

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q3	262 / 404	35%
大類：Medicine 小類：Endocrinology, Diabetes and Metabolism	Q3	165 / 244	32%
大類：Medicine 小類：Cancer Research	Q4	181 / 230	21%
大類：Medicine 小類：Endocrinology	Q4	103 / 128	19%
大類：Medicine 小類：Endocrine and Autonomic Systems	Q4	19 / 23	19%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書(shū)籍章節(jié)和數(shù)據(jù)論文。

Discover Oncology中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝 ONCOLOGY 腫瘤學(xué)	4區(qū) 4區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	2區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝 ONCOLOGY 腫瘤學(xué)	2區(qū) 2區(qū)

Discover Oncology JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	97 / 186	48.1%
學(xué)科：ONCOLOGY	SCIE	Q2	157 / 322	51.4%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	119 / 186	36.29%
學(xué)科：ONCOLOGY	SCIE	Q3	180 / 322	44.25%

Discover Oncology歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Discover Oncology中國(guó)學(xué)者發(fā)文選摘

1、WDR76 regulates 5-fluorouracil sensitivity in colon cancer via HRAS
Author: Hu, Yunlong; Tan, Xiao; Zhang, Lin; Zhu, Xiang; Wang, Xiangyao

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00656-9
2、OncoVee (TM)-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study
Author: Zhang, Baonan; Li, Yuzhen; Zhu, Xiaodan; Chen, Zhe; Huang, Xiaona; Gong, Tingjie; Zheng, Weiwang; Bi, Zhenle; Zhu, Chenyang; Qian, Jingyi; Li, Xiaoqiang; Jin, Chunhui

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00661-y
3、Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Author: Shi, Zhendong; Liu, Yingxue; Zhang, Shichao; Cai, Shuanglong; Liu, Xu; Meng, Jie; Zhang, Jin

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00660-z
4、Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells
Author: Wei, Zhijiang; Liu, Guiying; Jia, Rufu; Zhang, Wei; Li, Li; Zhang, Yuanyuan; Wang, Zhijing; Bai, Xiyong

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-022-00535-9
5、The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data
Author: Dai, Yuran; Ma, Shishi; Lan, Ailin; Wang, Yihua; Wang, Yu; Jin, Yudi; Ding, Nan; Jiang, Linshan; Tang, Zhenrong; Yin, Xuedong; Peng, Yang; Liu, Shengchun

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-022-00609-8
6、Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway
Author: Wang, Ganggang; Zhang, Xin; Zhou, Zhijie; Song, Chao; Jin, Wenzhi; Zhang, Hao; Wu, Weixin; Yi, Yong; Cui, Hengguan; Zhang, Ping; Liu, Xinyu; Xu, Weiqiang; Shen, Xiaowei; Shen, Weixing; Wang, Xiaoliang

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00611-8
7、Thoracic SMARCA4-deficient undifferentiated tumor
Author: Jiang, Jiapeng; Chen, Zhixin; Gong, Jiali; Han, Na; Lu, Hongyang

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00639-w
8、TEM1 up-regulates MMP-2 and promotes ECM remodeling for facilitating invasion and migration of uterine sarcoma
Author: Wu, Chenghao; Sun, Wenhuizi; Shen, Dongsheng; Li, Huaifang; Tong, Xiaowen; Guo, Yi

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00613-6